# BASF and Bota Biosciences Launch SkinNexus™ Collag3n

> Melding synthetic biology with industrial scalability, BASF and Bota Biosciences have commercially launched SkinNexus™ Collag3n. Debuted at in-cosmetics Global, the 100% human-identical, yeast-fermented recombinant Collagen III fragment targets the high-performance anti-aging cosmetics sector, demonstrating superior efficacy in cellular homeostasis and wrinkle reduction at low formulation use levels.

Published: 2026-07-10T06:37:00+00:00
Language: en
Categories: [Cosmetics and Personal Care](https://chemexworld.com/en/categories/sectors/cosmetics-and-personal-care.md)

Canonical URL:
https://chemexworld.com/en/news/basf-and-bota-biosciences-launch-skinnexus-collag3n

## Content

The global cosmetic ingredients market is adapting to industrial platforms driven by synthetic biology and machine learning. **BASF** and **Bota Biosciences** have announced the commercial rollout of **SkinNexus™ Collag3n**, a bio-identical vegan collagen active.

The product development pipeline combined Bota's Physical AI-driven biofoundry capabilities with BASF's cosmetic formulation expertise, allowing the joint engineering teams to screen **over 2,000 collagen fragments** while simultaneously validating industrial biomanufacturing feasibility.

### **Yeast Fermentation Architecture and Verified Dermal Homeostasis**

Engineered as a sustainable alternative to legacy animal-derived collagen, SkinNexus™ Collag3n introduces several precise biochemical and clinical parameters to personal care formulations:

- **100% Sequence Homology:** Produced via continuous yeast fermentation, the recombinant protein fragment exhibits a **100% human-identical sequence** for Tip III collagen targets.
- **Full-Spectrum Collagen Synthesis:** In vitro testing within 3D dermis tissue models demonstrated significant stimulation of natural structural proteins, registering increases of **+48% in Collagen I**, **+82% in Collagen III**, and **+71% in Collagen V**.
- **Low-Dosage Clinical Efficacy:** In vivo clinical trials conducted on female cohorts aged 53–70 demonstrated measurable improvements in skin sagging and wrinkle depth over a four-week application cycle. The bio-active outperformed a standard commercial collagen benchmark applied at ten times the concentration, enabling anti-aging efficacy at lower formulation dosages.

### **Establishing New Standards for Bio-Identical Actives**

**Lucilene Veira Nunes, Global Business Management at BASF Beauty Care Solutions:**

> *SkinNexus™ Collag3n reflects our commitment to high-performance, science-based innovation. Bota Biosciences was the partner of choice to combine strong biological efficacy with robust industrial scalability.*

**Dr. Cheryl Cui, Founder and CEO of Bota Biosciences:**

> *This collaboration is proof that Physical AI for Biomanufacturing can turn cutting-edge science into commercial, sustainable, and high-performance ingredients. Together with BASF, we are setting new standards for bio-identical actives.*